Stifel on MapLight Therapeutics (MPLT): 'The last point will likely be the pushback on the data'
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Buy rating and $36.00 price target on MapLight Therapeutics (NASDAQ: MPLT)The analyst comments "We're ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
